School of Biotechnology, National Institute of Technology Calicut, Calicut, Kerala, 673601, India.
Naunyn Schmiedebergs Arch Pharmacol. 2021 Jun;394(6):1231-1249. doi: 10.1007/s00210-021-02059-5. Epub 2021 Feb 23.
Econazole, miconazole, and sertaconazole, the structurally related azoles with imidazole moiety, were evaluated for their cytotoxicity and their ability to bind to mammalian tubulin. Our results indicated that sertaconazole and econazole bound to goat brain tubulin with a dissociation constant of 9 and 19 μM respectively, while miconazole did not bind to goat brain tubulin. Econazole, miconazole, and sertaconazole inhibited the proliferation of HeLa cells with an IC of 28, 98, and 38 μM respectively with sertaconazole alone inducing a mitotic block in the treated cells. Since sertaconazole bound to goat brain tubulin with higher affinity and blocked the cells at mitosis, we hypothesized that its cytotoxic mechanism might involve inhibition of tubulin and econazole which did not block the cells at mitosis may have additional targets than tubulin. Sertaconazole inhibited the polymerization of tubulin in HeLa cells and the in vitro assembled goat brain tubulin. Competitive tubulin-binding assay using colchicine and computational simulation studies showed that sertaconazole bound closer to the colchicine site and induced the tubulin dimer to adopt a "bent" conformation which is incompetent for the polymerization. Results from RT-PCR analysis of the A549 cells treated with sertaconazole indicated activation of apoptosis. Sertaconazole significantly inhibited the migration of HeLa cells and showed synergistic antiproliferative potential with vinblastine. Collectively, the results suggest that sertaconazole which is already in clinical practice could be useful as a topical chemotherapy agent for the treatment of skin cancers in combination with other systemic anticancer agents.
酮康唑、咪康唑和舍他康唑,这三种具有咪唑部分的结构相关唑类化合物,被评估了其细胞毒性及其与哺乳动物微管蛋白结合的能力。我们的结果表明,舍他康唑和酮康唑分别以 9 和 19 μM 的解离常数与山羊脑微管蛋白结合,而咪康唑则不与山羊脑微管蛋白结合。酮康唑、咪康唑和舍他康唑分别以 28、98 和 38 μM 的 IC 抑制 HeLa 细胞的增殖,而舍他康唑单独处理会导致细胞有丝分裂阻滞。由于舍他康唑与山羊脑微管蛋白结合的亲和力更高,并在有丝分裂时阻断细胞,我们假设其细胞毒性机制可能涉及微管蛋白的抑制,而不阻断细胞有丝分裂的酮康唑可能有比微管蛋白更多的靶点。舍他康唑抑制 HeLa 细胞中微管蛋白的聚合和体外组装的山羊脑微管蛋白的聚合。使用秋水仙碱进行的竞争性微管蛋白结合测定和计算模拟研究表明,舍他康唑更接近秋水仙碱结合位点,并诱导微管蛋白二聚体采用“弯曲”构象,这种构象不能进行聚合。用舍他康唑处理的 A549 细胞的 RT-PCR 分析结果表明细胞凋亡被激活。舍他康唑显著抑制 HeLa 细胞的迁移,并与长春碱表现出协同的抗增殖潜力。总之,这些结果表明,已经在临床实践中使用的舍他康唑可能与其他全身性抗癌药物联合作为治疗皮肤癌的局部化疗药物有用。